Compare XPOF & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPOF | EDIT |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.2M | 206.0M |
| IPO Year | 2021 | 2016 |
| Metric | XPOF | EDIT |
|---|---|---|
| Price | $7.21 | $3.49 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $8.13 | $4.92 |
| AVG Volume (30 Days) | 406.2K | ★ 1.5M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 35.24 | ★ 37.50 |
| EPS | ★ N/A | N/A |
| Revenue | $11,092,000.00 | ★ $31,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.91 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $3.83 | $1.23 |
| 52 Week High | $11.14 | $4.54 |
| Indicator | XPOF | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 58.18 | 79.31 |
| Support Level | $6.81 | $3.32 |
| Resistance Level | $8.32 | $3.58 |
| Average True Range (ATR) | 0.42 | 0.23 |
| MACD | 0.08 | 0.08 |
| Stochastic Oscillator | 74.87 | 92.04 |
Xponential Fitness Inc is a franchisor of boutique health and wellness brands. It operates a diversified platform of five brands spanning across verticals, including Pilates, barre, stretching, functional training, and yoga. Through its subsidiary, it offers an energetic, accessible, and personalized workout experience led by qualified instructors in studio locations throughout North America and internationally. The company's portfolio of brands includes Club Pilates; StretchLab; YogaSix; Pure Barre; and BFT. It operates in a single segment of the franchise business of its health and wellness brands.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.